It is the believe of many that tissue engineering (or as some
scientists prefer – regenerative medicine) is and will
increasingly be the focus of biomaterials research, justified
by a very significant and well-known clinical need for the
establishment of alternative therapies for the treatment of
tissue loss or end-stage organ failure, as the transplantation
of tissues or organs in these patients is often limited by
donor scarcity and is highly associated to the risk of rejection
and disease transfer. In this sense, tissue engineering
will lead to a great impact on health care providing in the
coming decades.